Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide

References

• MillsKTXuYZhangWA systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010Kidney Int20158895095726221752
   PubMed Web of Science ®Google Scholar
• BuemiMLacquanitiABolignanoDDialysis and the elderly: an underestimated problemKidney Blood Press Res200831533033618936550
   PubMed Web of Science ®Google Scholar
• HarounMKJaarBGHoffmanSCComstockGWKlagMJCoreshJRisk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, MarylandJ Am Soc Nephrol200314112934294114569104
   PubMed Web of Science ®Google Scholar
• LiuWYuFWuYA retrospective analysis of kidney function and risk factors by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in elderly Chinese patientsRen Fail2015371323132826211499
   PubMed Web of Science ®Google Scholar
• LacquanitiABolignanoDCampoSMalnutrition in the elderly patient on dialysisRen Fail200931323924519288330
   PubMed Web of Science ®Google Scholar
• LowSKSumCFYeohLYPrevalence of chronic kidney disease in adults with type 2 diabetes mellitusAnn Acad Med Singapore201545516417126198322
   PubMed Web of Science ®Google Scholar
• ThawornchaisitPDe LoozeFReidCMSeubsmanSATranTTSleighAThai Cohort Study TeamHealth-risk factors and the prevalence of chronic kidney disease: cross-sectional findings from a national cohort of 87 143 Thai open university studentsGlob J Health Sci201575597226156905
   PubMedGoogle Scholar
• KainzAHronskyMStelVSPrediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025Nephrol Dial Transplant201530Suppl 4iv113iv11826209733
   PubMed Web of Science ®Google Scholar
• BabuaCKalyesubulaROkelloEPattern and presentation of cardiac diseases among patients with chronic kidney disease attending a national referral hospital in Uganda: a cross sectional studyBMC Nephrol20151612626238594
   PubMed Web of Science ®Google Scholar
• MatsushitaKBallewSHCoreshJInfluence of chronic kidney disease on cardiac structure and functionCurr Hypertens Rep201517958126194332
   PubMed Web of Science ®Google Scholar
• PlutaAStróżeckiPKrintusMOdrowąż-SypniewskaGManitiusJLeft ventricular remodeling and arterial remodeling in patients with chronic kidney disease stage 1–3Ren Fail20153771105111026156686
   PubMed Web of Science ®Google Scholar
• CharytanDMCinelliAZeisbergEMAssociation of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burdenFibrogenesis Tissue Repair201581326213574
   PubMedGoogle Scholar
• Franczyk-SkóraBGluba-BrzózkaAWraniczJKBanachMOlszewskiRRyszJSudden cardiac death in CKD patientsInt Urol Nephrol201547697198225962605
   PubMed Web of Science ®Google Scholar
• CernaroVTrifiròGLorenzanoGLucisanoSBuemiMSantoroDNew therapeutic strategies under development to halt the progression of renal failureExpert Opin Investig Drugs2014235693709
   PubMed Web of Science ®Google Scholar
• CernaroVLacquanitiABuemiALupicaRBuemiMDoes erythropoietin always win?Curr Med Chem201421784985424059228
   PubMed Web of Science ®Google Scholar
• SinghAKSzczechLTangKLCHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney diseaseN Engl J Med2006355202085209817108343
   PubMed Web of Science ®Google Scholar
• PfefferMABurdmannEAChenCYTREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseN Engl J Med2009361212019203219880844
   PubMed Web of Science ®Google Scholar
• BuemiMCampoSCernaroVDonatoVLacquanitiAErythropoietin and the truths of scienceJ Nephrol201124556456821058263
   PubMed Web of Science ®Google Scholar
• MoeSDrüekeTCunninghamJKidney disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney Int200669111945195316641930
   PubMed Web of Science ®Google Scholar
• NickolasTLJamalSABone kidney interactionsRev Endocr Metab Disord201516215716326156535
   PubMed Web of Science ®Google Scholar
• KohNFujimoriTNishiguchiSSeverely reduced production of klotho in human chronic renal failure kidneyBiochem Biophys Res Commun200128041015102011162628
   PubMed Web of Science ®Google Scholar
• LarssonTOlausonHUn rapido aggiornamento su FGF23 per il nefrologo clinico. [A brief update on FGF23 for the clinical nephrologist]G Ital Nefrol2014312 Italian
   Google Scholar
• CernaroVSantoroDLucisanoSNicociaGLacquanitiABuemiMThe future of phosphate binders: a perspective on novel therapeuticsExpert Opin Investig Drugs2014231114591563
   PubMed Web of Science ®Google Scholar
• EzumbaIQuarlesLDKovesdyCPFGF23 e cuore. [FGF23 and the heart]G Ital Nefrol2014316 Italian
   Google Scholar
• SultanaJMusazziUMIngrasciottaYMedication is an additional source of phosphate intake in chronic kidney disease patientsNutr Metab Cardiovasc Dis2015251095996726165250
   PubMed Web of Science ®Google Scholar
• SavicaVCalòLAMonardoPSantoroDBellinghieriGPhosphate binders and management of hyperphosphataemia in end-stage renal diseaseNephrol Dial Transplant20062182065206816766546
   PubMed Web of Science ®Google Scholar
• LocatelliFDel VecchioLVioloLPontorieroGPhosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profilesExpert Opin Drug Saf201413555156124702470
   PubMed Web of Science ®Google Scholar
• BellinghieriGSantoroDSavicaVEmerging drugs for hyperphosphatemiaExpert Opin Emerg Drugs200712335536517874966
   PubMed Web of Science ®Google Scholar
• LiuLWangYChenHZhuXZhouLYangYThe effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trialsRen Fail20143681244125225019348
   PubMed Web of Science ®Google Scholar
• WangCLiuXZhouYNew conclusions regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trialsPLoS One2015107e013393826230677
   PubMed Web of Science ®Google Scholar
• ZhaiCJYangXWSunJWangREfficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysisInt Urol Nephrol201547352753525399356
   PubMed Web of Science ®Google Scholar
• CoppolinoGLucisanoSRivoliLSevalamer hydrochloride, sevelamer carbonate and lanthanum carbonate: in vitro and in vivo effects on gastric environmentTher Apher Dial201519547147625866250
   PubMed Web of Science ®Google Scholar
• ZhangCWenJLiZFanJEfficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic reviewBMC Nephrol20131422624134531
   PubMed Web of Science ®Google Scholar
• MakinoMKawaguchiKShimojoHNakamuraHNagasawaMKodamaRExtensive lanthanum deposition in the gastric mucosa: the first histopathological reportPathol Int2015651333725413959
   PubMed Web of Science ®Google Scholar
• HaratakeJYasunagaCOotaniAShimajiriSMatsuyamaAHisaokaMPeculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonateAm J Surg Pathol201539676777125602800
   PubMed Web of Science ®Google Scholar
• ZoccaliCMallamaciFCannata-AndíaJPhosphate binders and clinical outcomes in patients with stage 5D chronic kidney diseaseSemin Dial20152858759326278591
   PubMed Web of Science ®Google Scholar
• Wu-WongJRMizobuchiMIs there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?Expert Opin Investig Drugs2014231114651475
   PubMed Web of Science ®Google Scholar
• ItoKTakeshimaAShishidoKTreatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptomsTher Apher Dial201418Suppl 2192324975891
   PubMed Web of Science ®Google Scholar
• Astellas Pharm IncAstellas Submits Supplemental New Drug Application for Kiklin^® Capsules, a Treatment for Hyperphosphatemia, in JapanTokyoAstellas Pharm Inc2015 Available from: https://www.astellas.com/en/corporate/news/pdf/150317_1_Eg.pdfAccessed September 18, 2015
   Google Scholar
• SavicaVCalòLACaldareraRPhosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemiaNephron Physiol20071053p52p5517220638
   PubMedGoogle Scholar
• SavicaVCalòLAMonardoPSalivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patientsJ Am Soc Nephrol200920363964419020004
   PubMed Web of Science ®Google Scholar
• BlockGAPerskyMSShamblinBMEffect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney diseaseNephron Clin Pract20131231–29310123797006
   PubMed Web of Science ®Google Scholar
• SchmidHLedererSRNovel iron-containing phosphate binders for treatment of hyperphosphatemiaExpert Opin Pharmacother201516142179219126293683
   PubMed Web of Science ®Google Scholar
• MoustafaMLehrnerLAl-SaghirFA randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysisInt J Nephrol Renovasc Dis2014714115224748812
   PubMedGoogle Scholar
• WilhelmMGaillardSRakovVFunkFThe iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitroClin Nephrol201481425125824656315
   PubMed Web of Science ®Google Scholar
• http://www.velphoro.us [homepage on the Internet]Velphoro^® (sucroferric oxyhydroxide) chewable tabletsFresenius Medical Care North America2014 Available from: http://www.velphoro.usAccessed September 20, 2015
   Google Scholar
• ShahHHHazzanADFishbaneSNovel iron-based phosphate binders in patients with chronic kidney diseaseCurr Opin Nephrol Hypertens201524433033526050119
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002705/WC500175254.pdfAccessed September 20, 2015
   Google Scholar
• European Medicines AgencyAssessment report: VelphoroLondonEuropean Medicines Agency2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002705/WC500175257.pdfAccessed September 20, 2015
   Google Scholar
• GreigSLPloskerGLSucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysisDrugs201575553354225761962
   PubMed Web of Science ®Google Scholar
• CozzolinoMFunkFRakovVPhanOTeitelbaumIPreclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxideCurr Drug Metab2014151095396525658128
   PubMed Web of Science ®Google Scholar
• ChongEKaliaVWillsieSWinklePDrug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjectsJ Nephrol Epub201444
   PubMed Web of Science ®Google Scholar
• LABEL: VELPHORO-ferric oxyhydroxide tablet, chewable [webpage on the Internet]Bethesda, MDUnited States National Library of Medicine Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237da26c-f38c-4faa-93ad-735e71c9d0c1Accessed September 23, 2015
   Google Scholar
• GeisserPPhilippEPA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney diseaseClin Nephrol201074141120557860
   PubMed Web of Science ®Google Scholar
• WüthrichRPChoncholMCovicAGaillardSChongETumlinJARandomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patientsClin J Am Soc Nephrol20138228028923124782
   PubMed Web of Science ®Google Scholar
• FloegeJCovicACKettelerMPA21 Study GroupA phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patientsKidney Int201486363864724646861
   PubMed Web of Science ®Google Scholar
• FloegeJCovicACKettelerMLong-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patientsNephrol Dial Transplant20153061037104625691681
   PubMed Web of Science ®Google Scholar
• ChiuYWTeitelbaumIMisraMde LeonEMAdzizeTMehrotraRPill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patientsClin J Am Soc Nephrol2009461089109619423571
   PubMed Web of Science ®Google Scholar
• PhanOMaillardMMallucheHHStehleJCFunkFBurnierMEffects of sucroferric oxyhydroxide compared to lanthanum carbonate and sevelamer carbonate on phosphate homeostasis and vascular calcifications in a rat model of chronic kidney failureBiomed Res Int2015201551560626221597
   PubMed Web of Science ®Google Scholar
• BraithwaiteVPrenticeAMDohertyCPrenticeAFGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation studyInt J Pediatr Endocrinol2012201212723098062
   PubMedGoogle Scholar
• BhattacharyyaNChongWHGafniRICollinsMTFibroblast growth factor 23: state of the field and future directionsTrends Endocrinol Metab2012231261061822921867
   PubMed Web of Science ®Google Scholar
• DegerSMErtenYPasaogluOTThe effects of iron on FGF23-mediated Ca-P metabolism in CKD patientsClin Exp Nephrol201317341642323180041
   PubMed Web of Science ®Google Scholar
• BolignanoDCoppolinoGRomeoANeutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patientsNephrol Dial Transplant200924113398340319549696
   PubMed Web of Science ®Google Scholar
• PaiABJangSMWegryznNIron-based phosphate binders – a new element in management of hyperphosphatemiaExpert Opin Drug Metab Toxicol201516113
   Google Scholar